Every material Form 8-K Incyte has filed with the SEC since January 10, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Incyte reported third-quarter 2026 total revenue of $1.56 billion, up 14% from a year earlier, and raised its full-year 2026 total net sales guidance to $5,210-$5,300 million. GAAP net loss was $784.8 million, or $3.86 per diluted share, compared with net income of $424.2 million ($2.11 per share) a year earlier, mainly because of a one-time $1.23 billion in-process R&D expense tied to the Vega Therapeutics acquisition.
Total revenue was $1.56 billion, up 14%; Opzelura net sales were $255 million, up 36%
GAAP net loss of $784.8 million ($3.86 per diluted share) vs. net income of $424.2 million ($2.11) in Q3 2025
One-time $1.23 billion IPR&D expense from the Vega Therapeutics acquisition; non-GAAP diluted loss was $3.60 per share
2026 total net sales guidance raised to $5,210-$5,300 million from $5,130-$5,260 million; Opzelura guidance includes a one-time $246 million CMS-related benefit
Incyte reported second quarter 2026 total revenue of $1.67 billion, up 38%, and GAAP diluted EPS of $2.81 versus $2.04 a year earlier. The company raised its 2026 total net sales guidance to $5,130 to $5,260 million, but also raised GAAP operating expense guidance to $4,915 to $4,995 million, which includes an expected $1,270 million in-process R&D charge in the third quarter tied to the Vega Therapeutics acquisition. Quarterly sales were boosted by a one-time, non-cash $246 million Opzelura benefit.
Total revenue was $1.67 billion, up 38%; GAAP net income was $585.6 million versus $405.0 million
Total net sales were $1.49 billion, up 40%; excluding the one-time $246 million Opzelura benefit, net sales grew 17%
2026 total net sales guidance raised to $5,130 to $5,260 million from $4,770 to $4,940 million
Expected IPR&D expense of approximately $1,270 million in Q3 2026 related to the $1.25 billion Vega Therapeutics acquisition
Incyte reported first-quarter 2026 total revenue of $1.27 billion, up 21% from the prior year, with GAAP diluted EPS of $1.47 versus $0.80 a year earlier. The company reaffirmed all of its 2026 financial guidance categories and said cash, cash equivalents and marketable securities reached $4.0 billion as of March 31, 2026.
Total revenue was $1.27 billion, up 21% from $1.05 billion in Q1 2025; total net sales were $1.10 billion, up 20%.
GAAP net income was $303.3 million versus $158.2 million, and GAAP diluted EPS was $1.47 versus $0.80.
Jakafi net sales rose 7% to $758 million; GAAP cost of sales rose 43% to $104.5 million.
Full-year 2026 guidance was reaffirmed, including total net sales of $4,770 million to $4,940 million; Suketu Upadhyay was named Chief Financial Officer effective May 4, 2026.
Incyte director Susanne Schaffert notified the company on March 26, 2026 that she is resigning from its Board of Directors, effective April 15, 2026. The filing states the resignation was not due to any disagreement with the company on operations, policies or practices.
Susanne Schaffert notified Incyte on March 26, 2026 of her board resignation.
Resignation takes effect April 15, 2026.
Dr. Schaffert had served on the board since 2022.
The filing states no disagreement with the company led to the resignation.
Incyte announced title changes for four executives effective March 25, 2026. Pablo Cagnoni became President and Global Head of Research and Development, replacing William Meury as President while Meury remains Chief Executive Officer and a board member. The company said there were no changes to compensation arrangements for the affected executives.
Pablo J. Cagnoni named President, Incyte and Global Head of Research and Development, replacing William J. Meury as President
William J. Meury remains Chief Executive Officer and a member of the Board of Directors
Mohamed Issa's U.S. Oncology and U.S. Immunology businesses are being integrated into a single U.S. commercial organization
Matteo Trotta, Executive Vice President and General Manager, U.S. Dermatology, will leave Incyte following a transition period
Incyte reported fourth quarter and full year 2025 results, with total revenue of $1.51 billion for the quarter and $5.14 billion for the year, and full year net product revenue of $4.35 billion, above its prior guidance of $4.23 to $4.32 billion. The company also gave 2026 total net product revenue guidance of $4.77 to $4.94 billion, and GAAP net income rose to $299.3 million in the quarter from $201.2 million a year earlier.
Q4 2025 total revenue was $1.51 billion, up 28% year over year, including $100.0 million of milestone and contract revenue.
Full year 2025 GAAP net income was $1.29 billion, compared with $32.6 million in 2024, and GAAP diluted EPS was $6.41 versus $0.15.
2026 guidance: total net product revenue of $4.77 to $4.94 billion and total GAAP R&D and SG&A operating expenses of $3.495 to $3.675 billion.
Cash, cash equivalents and marketable securities were $3.6 billion at December 31, 2025, compared with $2.2 billion a year earlier.
Incyte Corporation disclosed that Hervé Hoppenot, its former Chairman and Chief Executive Officer, retired from the Company's Board of Directors, effective immediately, after notifying the Company on December 10, 2025. He had served on the board since 2014. The filing reports no successor, replacement, or change in compensation.
Hervé Hoppenot notified Incyte on December 10, 2025 of his retirement from the board.
Retirement is effective immediately, per the filing.
Hoppenot is a former Chairman and Chief Executive Officer and had been a director since 2014.
The filing was signed December 12, 2025 by Richard Hoffman, Executive Vice President and General Counsel.
Incyte reported third-quarter 2025 total revenues of $1.37 billion, up 20% from a year earlier, and GAAP net income of $424.2 million, or $2.11 per diluted share, compared with $106.5 million, or $0.54 per diluted share, in the prior-year quarter. The company raised its full-year 2025 net product revenue guidance to $4.23-$4.32 billion, while reiterating its guidance for cost of product revenues, R&D and SG&A expenses.
Total revenues were $1.37 billion, up 20%; total net product revenues were $1.15 billion, up 19%.
GAAP diluted EPS was $2.11 versus $0.54 a year earlier; GAAP net income was $424.2 million versus $106.5 million.
Jakafi net product revenue rose 7% to $791 million; Opzelura rose 35% to $188 million.
Full-year 2025 net product revenue guidance was raised to $4.23-$4.32 billion, from the prior range that the filing lists for Jakafi and other oncology products.
Incyte Corporation's board appointed Thomas Tray, its Vice President, Finance and Chief Accounting Officer, to also serve as principal financial officer, effective September 16, 2025. The filing discloses no compensation terms and no arrangements tied to the appointment, and Mr. Tray has been with the company since June 2005.
Board appointed Thomas Tray as principal financial officer on September 30, 2025, effective September 16, 2025
Tray already serves as Vice President, Finance and Chief Accounting Officer (principal accounting officer)
Tray, age 48, joined Incyte in June 2005 as Manager, External Reporting
Filing states no arrangements or understandings with other persons tied to the appointment
Incyte's Executive Vice President and Chief Financial Officer, Christiana Stamoulis, notified the company on August 4, 2025 that she intends to leave her role to pursue another opportunity. She will stay until September 16, 2025 to support a smooth transition, and the company has started the process of naming a successor.
Christiana Stamoulis, EVP and CFO, gave notice on August 4, 2025
Her departure is effective September 16, 2025
She will remain with the company until then to support the transition
Incyte has begun the process of appointing a successor CFO
Incyte reported second-quarter 2025 total revenues of $1,216 million, up 16% from a year earlier, and GAAP net income of $405 million, compared with a loss of $444.6 million in the prior-year quarter. The company raised its full-year 2025 guidance for Jakafi and other oncology net product revenues, while absorbing a $242.3 million charge from its contract dispute settlement with Novartis.
Total revenues were $1,216 million in Q2 2025, up 16% year over year; Jakafi net product revenues were $764 million, up 8%.
GAAP diluted EPS was $2.04, compared with a loss of $2.04 per share in Q2 2024.
Full-year 2025 Jakafi net product revenue guidance was raised to $3,000-$3,050 million from $2,950-$3,000 million; other oncology guidance was raised to $500-$520 million from $415-$455 million.
The Novartis contract dispute settlement led to a $242.3 million difference recorded in contract dispute settlement expense; Incyte paid Novartis $280.0 million.
Incyte said Hervé Hoppenot retired as President and Chief Executive Officer effective June 26, 2025, and will remain on the Board and serve as a special advisor under a transition agreement. The company also appointed William J. Meury as President and Chief Executive Officer and to the Board, effective the same day, with a $1,250,000 initial base salary and a 100% target bonus.
William J. Meury, age 57, was named President, CEO and director effective June 26, 2025; he was previously CEO of Karuna Therapeutics, which was acquired by Bristol-Myers Squibb.
Julian C. Baker, Lead Independent Director, became Chairman of the Board effective June 26, 2025.
Meury's offer letter provides a 36,101-share sign-on RSU award, 110,630 stock options, a 108,303-share target performance share award, and a one-time 125,000-share target performance share award.
Hoppenot will receive his current annual base salary of $1,395,731 for six months, then 50% of that rate, under a transition agreement with a term ending no later than the first anniversary of June 26, 2025.
At its June 10, 2025 annual meeting, Incyte stockholders approved an 8,500,000-share increase to the shares available under the 2010 Stock Incentive Plan, removed the fungible share ratio for future awards, and extended the plan's termination date by five years. They also approved a 1,000,000-share increase to the 1997 Employee Stock Purchase Plan, elected all nine director nominees, and ratified Ernst & Young LLP as auditor for 2025. Larger equity plan reserves allow more stock awards, which can dilute existing shareholders.
Stock Incentive Plan share reserve rises 8,500,000 shares, from 66,453,475 to 74,953,475
Employee Stock Purchase Plan reserve rises 1,000,000 shares, from 10,350,000 to 11,350,000
Non-binding say-on-pay vote: 153,838,972 for, 13,020,842 against, 571,301 abstentions
Ernst & Young LLP ratified as auditor for 2025: 166,830,874 for, 10,085,753 against
Incyte reported first quarter 2025 total revenues of $1.05 billion, up 20% from a year earlier, and GAAP diluted EPS of $0.80 versus $0.75. The company raised its full-year 2025 Jakafi net product revenue guidance to $2.95 billion to $3.00 billion, while GAAP net income fell to $158.2 million from $169.5 million.
Total revenues were $1,052.9 million in Q1 2025 versus $880.9 million in Q1 2024 (+20%); total net product revenues rose 26%.
Jakafi net product revenues were $709.4 million in Q1 2025 (+24%); full-year 2025 Jakafi guidance raised to $2,950 million to $3,000 million from $2,925 million to $2,975 million.
GAAP operating income was $205.2 million versus $91.9 million; GAAP net income was $158.2 million versus $169.5 million.
Cash, cash equivalents and marketable securities were $2.4 billion as of March 31, 2025, up from $2.2 billion at December 31, 2024.
Incyte reported fourth-quarter 2024 total revenues of $1.2 billion, up 16% year over year, and full-year revenues of $4.2 billion, up 15%. Full-year GAAP net income fell to $32.6 million from $597.6 million, mainly because of a $679.4 million charge for in-process R&D assets acquired with Escient and a $100.0 million milestone payment to MacroGenics. The company also gave 2025 guidance for Jakafi and Opzelura net product revenues.
Q4 2024 GAAP net income was $201.2 million, or $1.02 per diluted share, versus $201.1 million, or $0.89, a year earlier
Full-year 2024 GAAP diluted EPS was $0.15, compared with $2.65 in 2023
2025 guidance: Jakafi net product revenues of $2,925 million to $2,975 million; Opzelura $630 million to $670 million
Cash, cash equivalents and marketable securities were $2.2 billion at December 31, 2024, down from $3.7 billion, mainly due to a $2.0 billion share repurchase in June 2024
Incyte said Executive Vice President and General Manager, North America Barry P. Flannelly announced his retirement on January 6, 2025, and stepped down from that role that day. He will stay employed through July 31, 2025 to help transition his responsibilities until a successor begins work.
Barry P. Flannelly announced retirement and stepped down as EVP, General Manager, North America on January 6, 2025
Role change takes full effect when his successor starts employment; successor not named in the filing
Flannelly remains employed through July 31, 2025 to assist with the transition
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Incyte filing is on SEC EDGAR ↗. 8-K briefs of other companies →